286 related articles for article (PubMed ID: 8318268)
1. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees.
Natuk RJ; Lubeck MD; Chanda PK; Chengalvala M; Wade MS; Murthy SC; Wilhelm J; Vernon SK; Dheer SK; Mizutani S
AIDS Res Hum Retroviruses; 1993 May; 9(5):395-404. PubMed ID: 8318268
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration.
Lubeck MD; Natuk RJ; Chengalvala M; Chanda PK; Murthy KK; Murthy S; Mizutani S; Lee SG; Wade MS; Bhat BM
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1443-9. PubMed ID: 7888199
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus vectored vaccines.
Natuk RJ; Davis AR; Chanda PK; Lubeck MD; Chengalvala M; Murthy SC; Wade MS; Dheer SK; Bhat BM; Murthy KK
Dev Biol Stand; 1994; 82():71-7. PubMed ID: 7958485
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.
Natuk RJ; Chanda PK; Lubeck MD; Davis AR; Wilhelm J; Hjorth R; Wade MS; Bhat BM; Mizutani S; Lee S
Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7777-81. PubMed ID: 1502197
[TBL] [Abstract][Full Text] [Related]
5. Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag.
Zhao J; Voltan R; Peng B; Davis-Warren A; Kalyanaraman VS; Alvord WG; Aldrich K; Bernasconi D; Buttò S; Cafaro A; Ensoli B; Robert-Guroff M
Virology; 2005 Nov; 342(1):1-12. PubMed ID: 16109434
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen.
Leung L; Srivastava IK; Kan E; Legg H; Sun Y; Greer C; Montefiori DC; zur Megede J; Barnett SW
AIDS; 2004 Apr; 18(7):991-1001. PubMed ID: 15096801
[TBL] [Abstract][Full Text] [Related]
7. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
[TBL] [Abstract][Full Text] [Related]
8. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost.
Vinner L; Wee EG; Patel S; Corbet S; Gao GP; Nielsen C; Wilson JM; Ertl HCJ; Hanke T; Fomsgaard A
J Gen Virol; 2003 Jan; 84(Pt 1):203-213. PubMed ID: 12533717
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus.
Khattar SK; Palaniyandi S; Samal S; LaBranche CC; Montefiori DC; Zhu X; Samal SK
Hum Vaccin Immunother; 2015; 11(2):504-15. PubMed ID: 25695657
[TBL] [Abstract][Full Text] [Related]
11. Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice.
Bruce CB; Akrigg A; Sharpe SA; Hanke T; Wilkinson GWG; Cranage MP
J Gen Virol; 1999 Oct; 80 ( Pt 10)():2621-2628. PubMed ID: 10573155
[TBL] [Abstract][Full Text] [Related]
12. Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges.
Khattar SK; Manoharan V; Bhattarai B; LaBranche CC; Montefiori DC; Samal SK
mBio; 2015 Jul; 6(4):e01005. PubMed ID: 26199332
[TBL] [Abstract][Full Text] [Related]
13. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
AIDS Vaccine Evaluation Group 022 Protocol Team
J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
[TBL] [Abstract][Full Text] [Related]
14. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.
Egan MA; Chong SY; Rose NF; Megati S; Lopez KJ; Schadeck EB; Johnson JE; Masood A; Piacente P; Druilhet RE; Barras PW; Hasselschwert DL; Reilly P; Mishkin EM; Montefiori DC; Lewis MG; Clarke DK; Hendry RM; Marx PA; Eldridge JH; Udem SA; Israel ZR; Rose JK
AIDS Res Hum Retroviruses; 2004 Sep; 20(9):989-1004. PubMed ID: 15585086
[TBL] [Abstract][Full Text] [Related]
16. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316
[TBL] [Abstract][Full Text] [Related]
17. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
18. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees.
Barrett N; Eder G; Dorner F
Biotechnol Ther; 1991; 2(1-2):91-106. PubMed ID: 1845126
[TBL] [Abstract][Full Text] [Related]
20. Recombinant simian varicella viruses induce immune responses to simian immunodeficiency virus (SIV) antigens in immunized vervet monkeys.
Ou Y; Traina-Dorge V; Davis KA; Gray WL
Virology; 2007 Aug; 364(2):291-300. PubMed ID: 17434552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
